Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Malignant neoplasm progression
ADR ID BADD_A05037
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.16      Miscellaneous and site unspecified neoplasms malignant and unspecified
16.16.01      Neoplasms malignant site unspecified NEC
16.16.01.005      Malignant neoplasm progression
Description Not Available
MedDRA Code 10051398
MeSH ID Not Available
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Malignant neoplasm aggravated | Neoplasm malignant aggravated | Malignant neoplasm progression | Progression of pre-existing cancer
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D02489Neratinib--
BADD_D02495Duvelisib0.001075%
BADD_D02498Abemaciclib0.005462%
BADD_D02500Alpelisib0.004522%
BADD_D02505Gilteritinib0.000336%
BADD_D02506Erdafitinib0.000112%
BADD_D02509Brigatinib0.001589%
BADD_D02510Rucaparib0.076402%
BADD_D02524Ivosidenib0.000224%
BADD_D02526Larotrectinib0.000828%
BADD_D02528Asciminib0.000392%
BADD_D02540Capmatinib0.002854%
BADD_D02548Darolutamide0.002069%
BADD_D02552Encorafenib--
BADD_D02566Lurbinectedin0.000448%
BADD_D02567Lutetium lu-177 vipivotide tetraxetan-
BADD_D02568Lutetium oxodotreotide lu-177-
BADD_D02573Mobocertinib0.001791%
BADD_D02586Radium ra-223 dichloride-
BADD_D02591Ripretinib0.000392%
BADD_D02593Selpercatinib0.000448%
BADD_D02594Selumetinib0.000112%
BADD_D02596Sotorasib0.000660%
BADD_D02598Tazemetostat0.000112%
BADD_D02600Tivozanib0.000246%
BADD_D02603Tucatinib0.001522%
BADD_D02629Niraparib--
The 4th Page    First    Pre   4    Total 4 Pages